Tarsus Pharmaceuticals Inc
TARS40.519USD
-0.291-0.71%
交易中 （美东）报价延迟15分钟
1.70B总市值
亏损市盈率 TTM
关于 Tarsus Pharmaceuticals Inc 公司
Tarsus Pharmaceuticals, Inc. 是一家商业阶段的生物制药公司。该公司专注于治疗药物的开发和商业化，从眼部护理开始。该公司的主要候选产品 XDEMVY 是一种洛蒂兰眼科溶液，可针对并根除蠕形螨眼睑炎的根本原因——蠕形螨感染。XDEMVY 的活性药物成分 (API) 洛蒂兰通过抑制寄生虫特异性 γ-氨基丁酸门控氯离子通道来麻痹和根除螨虫和其他寄生虫。该公司正在研究其候选产品的开发，以解决具有高度未满足医疗需求的目标疾病，其中包括用于治疗睑板腺疾病 (MGD) 的 TP-03、用于治疗红斑痤疮的新型凝胶制剂 TP-04 和用于预防莱姆病和减少社区疟疾的新型口服制剂 TP-05。
公司简介
公司代码TARS
公司名称Tarsus Pharmaceuticals Inc
上市日期Oct 16, 2020
CEOMr. Bobak (Bobby) Azamian, M.D., Ph.D.
员工数量323
证券类型Ordinary Share
年结日Oct 16
公司地址15440 Laguna Canyon Road
城市IRVINE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编92618
电话19494099820
网址https://www.tarsusrx.com/
公司代码TARS
上市日期Oct 16, 2020
CEOMr. Bobak (Bobby) Azamian, M.D., Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. William J. Link, Ph.D.
Dr. William J. Link, Ph.D.
Independent Director
Independent Director
180.89K
+1.89%
Dr. Seshadri Neervannan, Ph.D.
Dr. Seshadri Neervannan, Ph.D.
Chief Operating Officer
Chief Operating Officer
79.68K
+23.03%
Dr. Bryan Wahl, M.D., J.D.
Dr. Bryan Wahl, M.D., J.D.
General Counsel, Secretary
General Counsel, Secretary
49.09K
+24.08%
Mr. Aziz Mottiwala
Mr. Aziz Mottiwala
Chief Commercial Officer
Chief Commercial Officer
47.56K
-26.90%
Ms. Dianne C. Whitfield
Ms. Dianne C. Whitfield
Chief Human Resources Officer
Chief Human Resources Officer
44.38K
+37.80%
Mr. Jeffrey S. (Jeff) Farrow
Mr. Jeffrey S. (Jeff) Farrow
Chief Financial Officer and Chief Strategy Officer
Chief Financial Officer and Chief Strategy Officer
36.70K
+63.63%
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Lead Independent Director
Lead Independent Director
13.70K
+32.37%
Dr. Bhaskar Chaudhuri, Ph.D.
Dr. Bhaskar Chaudhuri, Ph.D.
Independent Director
Independent Director
8.70K
+62.62%
Dr. Andrew Goldberg, M.D.
Dr. Andrew Goldberg, M.D.
Independent Director
Independent Director
--
--
Dr. Elizabeth Yeu, M.D.
Dr. Elizabeth Yeu, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. William J. Link, Ph.D.
Dr. William J. Link, Ph.D.
Independent Director
Independent Director
180.89K
+1.89%
Dr. Seshadri Neervannan, Ph.D.
Dr. Seshadri Neervannan, Ph.D.
Chief Operating Officer
Chief Operating Officer
79.68K
+23.03%
Dr. Bryan Wahl, M.D., J.D.
Dr. Bryan Wahl, M.D., J.D.
General Counsel, Secretary
General Counsel, Secretary
49.09K
+24.08%
Mr. Aziz Mottiwala
Mr. Aziz Mottiwala
Chief Commercial Officer
Chief Commercial Officer
47.56K
-26.90%
Ms. Dianne C. Whitfield
Ms. Dianne C. Whitfield
Chief Human Resources Officer
Chief Human Resources Officer
44.38K
+37.80%
Mr. Jeffrey S. (Jeff) Farrow
Mr. Jeffrey S. (Jeff) Farrow
Chief Financial Officer and Chief Strategy Officer
Chief Financial Officer and Chief Strategy Officer
36.70K
+63.63%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月23日 周五
更新时间: 5月23日 周五
持股股东
股东类型
持股股东
持股股东
占比
RTW Investments L.P.
7.89%
BlackRock Institutional Trust Company, N.A.
6.74%
Paradigm BioCapital Advisors LP
6.21%
Jennison Associates LLC
5.87%
Tang Capital Management, LLC
5.84%
Other
67.44%
持股股东
持股股东
占比
RTW Investments L.P.
7.89%
BlackRock Institutional Trust Company, N.A.
6.74%
Paradigm BioCapital Advisors LP
6.21%
Jennison Associates LLC
5.87%
Tang Capital Management, LLC
5.84%
Other
67.44%
股东类型
持股股东
占比
Investment Advisor
32.82%
Hedge Fund
30.26%
Investment Advisor/Hedge Fund
28.62%
Research Firm
10.92%
Private Equity
4.88%
Individual Investor
3.36%
Pension Fund
0.34%
Bank and Trust
0.23%
Insurance Company
0.03%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
401
46.02M
109.53%
-4.01M
2025Q1
407
48.50M
115.53%
-3.34M
2024Q4
378
44.81M
116.78%
-6.00M
2024Q3
339
47.74M
124.97%
+1.40M
2024Q2
315
44.21M
116.20%
+181.38K
2024Q1
291
44.53M
119.96%
+4.60M
2023Q4
241
35.50M
106.12%
-146.85K
2023Q3
226
34.34M
108.40%
+5.84M
2023Q2
202
25.92M
97.99%
-1.52M
2023Q1
186
24.53M
93.13%
-2.70M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
RTW Investments L.P.
3.32M
7.89%
+79.48K
+2.46%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.83M
6.74%
-82.65K
-2.84%
Mar 31, 2025
Paradigm BioCapital Advisors LP
2.61M
6.21%
+78.30K
+3.09%
Mar 31, 2025
Jennison Associates LLC
2.49M
5.93%
-7.49K
-0.30%
Mar 31, 2025
Tang Capital Management, LLC
2.45M
5.84%
+200.00K
+8.87%
Mar 31, 2025
Deep Track Capital LP
1.48M
3.53%
+1.48M
--
Mar 31, 2025
The Vanguard Group, Inc.
2.22M
5.28%
+111.43K
+5.28%
Mar 31, 2025
TD Securities, Inc.
1.87M
4.46%
-34.48K
-1.81%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.74M
4.15%
+215.40K
+14.10%
Mar 31, 2025
Frazier Life Sciences Management, L.P.
1.40M
3.33%
-190.00K
-11.97%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
SPDR S&P Pharmaceuticals ETF
3.77%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.67%
Invesco Pharmaceuticals ETF
2.62%
Virtus LifeSci Biotech Products ETF
1.91%
ALPS Medical Breakthroughs ETF
1.15%
Harbor Human Capital Factor US Small Cap ETF
0.88%
iShares U.S. Pharmaceuticals ETF
0.78%
First Trust Small Cap Growth AlphaDEX Fund
0.43%
VictoryShares US Small Mid Cap Value Momentum ETF
0.25%
First Trust Small Cap Core Alphadex Fund
0.23%
查看更多
SPDR S&P Pharmaceuticals ETF
占比3.77%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
占比2.67%
Invesco Pharmaceuticals ETF
占比2.62%
Virtus LifeSci Biotech Products ETF
占比1.91%
ALPS Medical Breakthroughs ETF
占比1.15%
Harbor Human Capital Factor US Small Cap ETF
占比0.88%
iShares U.S. Pharmaceuticals ETF
占比0.78%
First Trust Small Cap Growth AlphaDEX Fund
占比0.43%
VictoryShares US Small Mid Cap Value Momentum ETF
占比0.25%
First Trust Small Cap Core Alphadex Fund
占比0.23%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
